3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
Fluorouracil
4
Filgrastim
4
Cetuximab
3
fludarabine
2
cemiplimab
2
belinostat
2
atezolizumab
2
Temozolomide
2
Riluzole
2
Peripheral Blood Stem Cell Transplantation
2
Oncolytic Virotherapy
2
Nivolumab
2
Ipilimumab
2
Cyclophosphamide
2
Bortezomib
2
AH 111585
2
zanidatamab
1
vocimagene amiretrorepvec
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
toripalimab
1
spartalizumab
1
seribantumab
1
selpercatinib
1
repotrectinib
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Radionuclide Imaging
×
Sarcoma
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled